Report overview
This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy Drugs. This report contains market size and forecasts of Duchenne Muscular Dystrophy Drugs in global, including the following market information:
Global Duchenne Muscular Dystrophy Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Duchenne Muscular Dystrophy Drugs market was valued at US$ 1041.1 million in 2022 and is projected to reach US$ 7464.7 million by 2029, at a CAGR of 32.5% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Molecular-based Therapies Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Duchenne Muscular Dystrophy Drugs include Biogen, Roche, Daiichi Sankyo, Pfizer, Cumberland Pharmaceuticals, Santhera Pharmaceuticals, Taiho Pharmaceutical, Teijin Pharma and Akashi Therapeutics, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Duchenne Muscular Dystrophy Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Duchenne Muscular Dystrophy Drugs Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Duchenne Muscular Dystrophy Drugs Market Segment Percentages, by Type, 2022 (%)
Molecular-based Therapies
Steroid Therapy
Other
Global Duchenne Muscular Dystrophy Drugs Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Duchenne Muscular Dystrophy Drugs Market Segment Percentages, by Application, 2022 (%)
Hospitals
Clinics
Others
Global Duchenne Muscular Dystrophy Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Duchenne Muscular Dystrophy Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Duchenne Muscular Dystrophy Drugs revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Duchenne Muscular Dystrophy Drugs revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Biogen
Roche
Daiichi Sankyo
Pfizer
Cumberland Pharmaceuticals
Santhera Pharmaceuticals
Taiho Pharmaceutical
Teijin Pharma
Akashi Therapeutics
Sarepta Therapeutics
BioMarin
Fibrogen Inc
Nobelpharma Co. Ltd
Eloxx Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Duchenne Muscular Dystrophy Drugs, market overview.
Chapter 2: Global Duchenne Muscular Dystrophy Drugs market size in revenue.
Chapter 3: Detailed analysis of Duchenne Muscular Dystrophy Drugs company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Duchenne Muscular Dystrophy Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
